Treatment with Delta-9-tetrahydrocannabinol/cannabidiol in Multiple Sclerosis: Influence on the Autonomy Profile according to the International Classification of Functioning, Disability and Health
  • Silvia Ciotti
    USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy
  • Mary Micheli
    USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy
  • Antonella Cometa
    USL Umbria 2, Department of Rehabilitation, S.M. Stella, Orvieto, Italy
  • Claudia De Carlo
    USL Umbria 2, Department of Rehabilitation, Domus Gratiae, Terni, Italy
  • Giancarlo Martini
    USL Umbria 2, Department of Rehabilitation, Ospedale di Cascia, Cascia, Italy
  • Andrea Marona
    Department of Neuroradiology, USL Umbria 2, Ospedale S.G. Battista, Foligno, Italy
  • Laura Filippetti
    USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy
  • Diego Carducci
    USL Umbria 2, Department of Rehabilitation and Neurology, Ospedale S.G. Battista, Foligno, Italy
  • Silvano Baratta
    USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy
  • Mauro Zampolini
    USL Umbria 2, Department of Rehabilitation and Neurology, Ospedale S.G. Battista, Foligno, Italy
  • Francesco Corea
    USL Umbria 2, Department of Rehabilitation and Neurology, Ospedale S.G. Battista, Foligno, Italy

Keywords

Multiple sclerosis, ICF, neurorehabilitation, delta-9-tetrahydrocannabinol/cannabidiol

Abstract

Multiple sclerosis (MS) is the most common cause of non-traumatic neurological disability in young adults. It has effects at different levels: physical, emotional, psychological, cognitive and social, with a great variety of signs and symptoms. In particular, spasticity contributes to reducing the motor performance of patients with MS, causing pain, reduction in distance walked and limitations in social life. We present the case of a 39-year-old woman with MS. She was treated with delta-9-tetrahydrocannabinol/cannabidiol and the outcome was assessed with the International Classification of Functioning Disability and Health core set framework.

VIEW THE ENTIRE ARTICLE

References

  • Wicks CR, Ward K, Stroud A, Tennant A, Ford HL . Multiple sclerosis and employment: associations of psychological factors and work instability. J Rehabil Med 2016; 48799 –805.
  • WHO. International Classification of Functioning, Disability and Health. Trento: Erickson; 2002.
  • Holper L, Coenen M, Weise A, Stucki G, Cieza A, Kesselring J. Characterization of functioning in multiple sclerosis using the ICF. J Neurol 2010;257(1):103–113.
  • Corea F, Barbi M, Bellanti A, Ciotti S, Micheli S, Brustenghi P, et al. Analysis of activities and participation according to the International Classification of Functioning (ICF) Stroke Core Set on a cohort of ischemic stroke survivors. Cerebrovasc Dis 2014;71(Suppl): 72.
  • Scarponi F, Sattin D, Leonardi M, Raggi A, Zampolini M. The description of severe traumatic brain injury in light of the ICF classification. Disabil Rehabil 2009;31(Suppl 1): S134–S143.
  • Ciotti S, Bianconi F, Saraceni VM, Vulpiani MC, Rinonapoli G, Zampolini M, et al. Narrative medicine in amyotrophic lateral sclerosis and a rehabilitation project based on International Classification of Functioning, Disability and Health. Am J Phys Med Rehabil 2018;97(11):832–838.
  • Coenen M, Cieza A, Freeman J, Khan F, Miller D, Weise A, et al. The development of ICF Core Sets for multiple sclerosis: results of the International Consensus Conference. J Neurol 2011;258(8):1477–1488.
  • Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, et al. The Italian MultipleSclerosis Register. Neurol Sci 2019;40(4):907.
  • Carotenuto A, Costabile T, De Lucia M, Moccia M, Falco F, Petruzzo M, et al.Predictors of nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study. J Neurol 2020;267(6):1737–1743. doi: 10.1007/s00415-020-09739-x.
  • Views: 301
    HTML downloads: 69
    PDF downloads: 119


    Published: 2021-10-08
    Issue: 2021: Vol 8 No 9 (view)


    How to cite:
    1.
    Ciotti S, Micheli M, Cometa A, De Carlo C, Martini G, Marona A, Filippetti L, Carducci D, Baratta S, Zampolini M, Corea F. Treatment with Delta-9-tetrahydrocannabinol/cannabidiol in Multiple Sclerosis: Influence on the Autonomy Profile according to the International Classification of Functioning, Disability and Health. EJCRIM 2021;8 doi:10.12890/2021_002298.

    Most read articles by the same author(s)